Square Pharmaceuticals (SQURPHARMA) Q3 2025 earnings summary

Executive summary

• Consolidated net revenue for the nine months ended 31 March 2025 rose 11.1% year-over-year to Tk. 57.85 billion, with net profit after tax up 11.8% to Tk. 18.75 billion.

• Standalone net revenue for the parent company reached Tk. 45.31 billion, up 2.3% year-over-year, with net profit after tax at Tk. 11.62 billion.

• Earnings per share (EPS) for the consolidated group increased to Tk. 21.15 from Tk. 18.24, while standalone EPS was Tk. 13.11 versus Tk. 13.76 in the prior year period.

Financial highlights

• Consolidated gross profit margin for the nine months was 47.5%, with gross profit of Tk. 27.50 billion.

• Consolidated operating profit reached Tk. 16.31 billion, up from Tk. 15.67 billion year-over-year.

• Consolidated income from investments surged to Tk. 4.56 billion, up 38.6% year-over-year.

• Net asset value (NAV) per share for the group increased to Tk. 151.94 from Tk. 142.05; standalone NAV per share was Tk. 121.18.

• Net operating cash flow per share declined to Tk. 11.90 (consolidated) and Tk. 10.96 (standalone) due to absence of prior year one-off items.

Outlook and guidance

• Management notes continued business growth and positive asset performance, with no intention to dispose of assets.

• No significant post-period events or changes in business seasonality were reported.